viimane versioon :
22/08/2024
Infostab
ingredientide nimekiri
nimekiri
Sobivus otsing
Y-liini sobivuse tabel
Viited
uurimisrühmad
valistab
plakat
Sidemed
sponsorid
Autor
Kasutusjuhend
ajakiri
Ganciclovir sodium
keemiline struktuur
Kaubanduslikud nimed erinevates maades
Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist
Ceptyl
Mehhiko
Ciganclor
Argentiina
Citovirax
Itaalia
Cymevan
Prantsusmaa
Cymeven
Saksamaa
Cymevene
Araabia Ühendemiraadid, Austraalia, Austria, Belgia, Brasiilia, Ecuador, Egiptus, Hispaania, Holland, Horvaatia, Iirimaa, Iraan, Island, Itaalia, Kolumbia, Kreeka, Luksemburg, Malaisia, Maroko, Mehhiko, Norra, Poola, Portugal, Rootsi, Soome, Suurbritannia, Sveits, Taani, Tšiili, Türgi, Ungari, uus-Meremaa, vene, Venetsueela
Cymevir
Brasiilia
Cytovene
Ameerika ühendriigid, Kanada
Ganciclovir
Ameerika ühendriigid, Argentiina, Ecuador, Kanada, Mehhiko, Prantsusmaa, Saksamaa, Tšiili
Gavir
India
Inglav
Mehhiko
Natclovir
India
Pharcigave
Mehhiko
Umecortil
Kolumbia, Mehhiko
Viraprex
Mehhiko
Viited : Ganciclovir sodium
tüüp
avaldamine
3
ajaleht
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
4
ajaleht
Zazempa V, Morgenszejn J, Paul M, Astier A.
Reconstitution centralisée du ganciclovir : méthode de contrôle et étude de stabilité.
Act Pharm Biol Clin 1995 ; 8: 525-528.
36
ajaleht
Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC.
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.
Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59
ajaleht
Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
67
ajaleht
Outman WR, Mitrano FP, Baptista RJ.
Visual compatibility of ganciclovir sodium and parenteral nutrient solution during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 1538-1539.
69
ajaleht
Visor GC, Lin LH, Jackson SE, Winterle JS, Lee G, Kenley RA.
Stability of ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections.
Am J Hosp Pharm 1986 ; 43: 2810-2812.
70
ajaleht
Silvestri AP, Mitrano FP, Baptista RJ, Williams DA.
Stability and compatibility of ganciclovir sodium in 5% dextrose injection over 35 days.
Am J Hosp Pharm 1991 ; 48: 2641-2643.
72
ajaleht
Johnson CE, Jacobson PA, Chan E.
Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions.
Am J Hosp Pharm 1994 ; 51: 503-508.
73
ajaleht
Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
74
ajaleht
Mulye NV, Turco SJ, Speaker TJ.
Stability of ganciclovir sodium in an infusion-pump syringe.
Am J Hosp Pharm 1994 ; 51: 1348-1349.
76
ajaleht
Parasrampuria J, Li LC, Stelmach AH, Sykes TR, Gordon GA.
Stability of ganciclovir sodium in 5% dextrose injection and in 0.9% sodium chloride injection over 35 days.
Am J Hosp Pharm 1992 ; 49: 116-118.
81
ajaleht
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84
ajaleht
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
88
ajaleht
Mole L, Oliva C, O?Hanley P.
Extended stability of ganciclovir for outpatient parenteral therapy for cytomegalovirus retinitis.
J Acquired Immune Defic Syndr 1992 ; 5: 354-358.
99
ajaleht
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169
ajaleht
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182
ajaleht
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
201
ajaleht
Thompson DF, Allen LV, Stiles ML.
Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2530-2531.
244
ajaleht
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
245
ajaleht
Phaypradith S, Vigneron J, Perrin A, Durney-Archeray MJ, Hoffman MA, Hoffman M.
Stability of ganciclovir sodium (Cymevan*) after dilution in PVC infusions and polypropylene syringes.
J Pharm Belg 1992 ; 47: 494-498.
248
ajaleht
Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249
ajaleht
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251
ajaleht
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253
ajaleht
Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
299
ajaleht
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300
ajaleht
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301
ajaleht
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307
ajaleht
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334
ajaleht
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335
ajaleht
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
479
ajaleht
Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
492
ajaleht
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
496
ajaleht
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
604
Labor
Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998
905
ajaleht
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921
ajaleht
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1410
ajaleht
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415
ajaleht
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423
ajaleht
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1625
ajaleht
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1754
ajaleht
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1925
ajaleht
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953
ajaleht
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982
ajaleht
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247
ajaleht
Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3626
Labor
Tacrolimus (Prograf®) - Résumé des Caractéristiques du Produit
Astellas Pharma 2014
3662
Labor
Foscavir (Foscarnet®) - Summary of Product Characteristics
Clinigen 2014
3728
ajaleht
Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3791
plakat
Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3796
ajaleht
Morlet N, Young S, Naidoo D et al.
High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study.
Br Ophtalmol 1995 ; 79: 753-755.
3883
Labor
Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016
4021
ajaleht
Guichard N, Bonnabry P, Rudaz S, Fleury S.
Long-term stability of ganciclovir in polypropylene containers at room temperature.
J Oncol Pharm Practice 2017 ;25,2: 303-308
4521
ajaleht
Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020
Mentions Légales